In Both Acute Pain Models, MR-107A-02 Demonstrated Statistically Significant and Clinically Meaningful Improvement in Pain Compared to Placebo, Significant Reduction in Opioid Usage and Superior Pain ...

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve ...

Revolution Medicines expects top-line data from the Phase III RASolute 302 trial in second-line PDAC in 1H 2026; the study is designed as an OS event-driven program and is powered primarily for ...

In power distribution systems, three-phase transformer configuration directly impacts system reliability and load management. Understanding the trade-offs between Delta and Wye connections enables ...

X-TOLE2 met primary endpoint in both dose groups, including -53.2% median percent change (MPC) from baseline in monthly FOS frequency with 25 mg ...